Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Directing money to in-state research was important to fundraisers.
Cutting off avenues for growth is key to killing tumors.
Since 1976, PC students, teachers and parents have given to OMRF.
Rockers Alice Cooper and Shooter Jennings come out to support research
Clinical trials for the experimental hearing loss prevention drug are being planned